| 초록 |
Objectives: In our study, we tried to investigate whether erythropoietin (EPO) responsiveness can be associated with nutritional, hydration status in hemodialysis (HD) patients undergoing NESP® (darbepoetin-alfa; Kyowa Kirin Korea Co., Ltd.) treatment.
Methods: The target hemoglobin (Hb) level is 1011 g/dL according to the Korean reimbursement guideline. Dose adjustments of NESP® were made according to the Hb level measured monthly in our facility. Every study population had more than 24 monthly Hb data points. In addition, the EPO resistance index (ERI) was calculated by dividing the weekly average darbepoetin-alfa dose by the Hb level. All of them were measured by BCM® (Fresenius Medical Care a Deutschland GmbH, Germany) to assess the hydration and nutritional status three times (Baseline, 12 Mos, 24 Mos). Routine biochemical tests were also taken into account.
Results: 1) In this study (n=98), the mean age of the patients was 64.0 ± 11.9 years, and 55.0% were male. 2) We divided into tertiles (T) according to the ERI. The average ERI was 0.02 ± 0.01, 0.04 ± 0.01, and 0.07 ± 0.03 in ERI-T1, ERI-T2, and ERI-T3, respectively. The ERI-T3 group had the lower Hb level whereas administration dose of EPO were higher in ERI-T3 (p < 0.05). 3) The ERI-T3 group had the lower phase angle (PhA) value, BMI and FTI (p < 0.05). Overhydration (OH) was higher in the ERI-T3 group (p < 0.05). (Table 1). 4) In multiple linear regression analysis, FTI was negatively associated with ERI (β= -0.218, respectively; p < 0.05, Table 2).
Conclusions: In HD patients with higher ERI, OH were increased whereas PhA, BMI and FTI were decreased. Therefore, EPO responsiveness is associated with nutritional, hydration status in hemodialysis patients undergoing darbepoetin-alfa treatment.
|